People’s United Financial reported net income of $62.1 million, or $0.20 per diluted share, in the second quarter of 2013 compared with $64.8 million, or $0.20 per diluted share, in the second quarter of 2012. Loans across all categories showed strong growth during the quarter, increasing at an annualized rate of 13%. The net interest margin declined to 3.33% for the second quarter compared with … Continue reading PBCT Loan Segment Shows Growth
Chipotle saw a nice sequential uptick in comparable restaurant sales during the second quarter, with much of the 5.5% increase stemming from ongoing peak-hour traffic throughput efforts as well as greater call-to-action marketing. Entering the quarter, there were concerns that competitive pressures (emergent fast-casual restaurant competition and more aggressive promotional activity from traditional quick-service and casual-dining players) might neutralize some of the throughput and marketing … Continue reading Comparable Sales Look Good For Chipotle
Mergers and acquisitions were back in the news last week with Auxilium Pharmaceuticals (AUXL) being the target this time around. The company, which is looking to acquire QLT Inc (QLTI), received a proposal from Endo International plc (ENDP). Other updates last week include the usual regulatory and pipeline-related news. Gilead remained in the news thanks yet again to its hepatitis C virus (HCV) treatment, Sovaldi. … Continue reading Biotech Stock News: A Weekly Analysis of Major Biotech Stocks
U.S. Bancorp USB reported net income of attributable to common shareholders of $1.4 billion, or $0.76 per diluted share, for the second quarter of 2013 compared with $1.3 billion, or $0.71 per diluted share, for the second quarter of 2012. Loans grew 7.4% compared with a year ago, primarily in commercial and residential loans. Low interest rates, primarily in investment securities, continued to pressure yields … Continue reading Loans Help Boost 2Q for USB
Halozyme Therapeutics, Inc (HALO) announced that the FDA has lifted the clinical hold from a phase Ib/II study (Study S1313). The study is evaluating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with a modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients suffering from metastatic pancreatic adenocarcinoma. The Study S1313, which is being sponsored and conducted by SWOG (a cancer research cooperative group funded primarily by the National … Continue reading Halozyme’s Clinical Hold Lifted by FDA : Biotech
Genuine Parts Company reported earnings per share of $1.17, $0.04 less than the Street consensus but $0.09 better than year-ago EPS. The Street was expecting better performance from Genuine Parts’ office products and electrical wholesale operations. With the automotive group performing well and our expectation that the industrial and electrical/electronic (EIS) groups should improve as the year progresses, plus the accretion from the Exego acquisition, … Continue reading GPC Misses Street EPS Estimate
